Sanofi’s combination diabetes drug hits goal in late-stage trial
Sanofi said on Wednesday a first late-stage Phase III study of its LixiLan diabetes drug had met its main target, while another would be completed at the end of the third quarter. LixiLan consists of a single-injection combination of Lyxumia, a drug developed with Danish drugmaker Zealand Pharma, and Sanofi's Lantus. It targets patients suffering from type 2 diabetes.